The cerebral-protection hypothesis was tested in induced rat injury and cultured rat neurons.
Investigators used middle-cerebral-artery occlusion followed by reperfusion in rats and oxygen–glucose deprivation with reoxygenation in primary cortical neurons. Remimazolam was associated with smaller infarct volumes, improved neurological scores and favorable cell-injury measures. Molecular and imaging assays supported involvement of the NF-kappa-B/NLRP3 inflammatory pathway and reduced pyroptotic injury.
Induced injury in young laboratory animals differs from heterogeneous human stroke, reperfusion treatment and comorbidity. Molecular changes support a proposed pathway but do not establish clinical neurological benefit during routine sedation. Exposure schedules and concentrations must be considered before extrapolating, and a preclinical comparison cannot establish human superiority to another anesthetic.
In a stroke-related opinion, distinguish the anesthetic’s sedative purpose from an experimental neuroprotective hypothesis. A patient receiving remimazolam cannot be assumed to have had inflammation reduced or tissue saved through this pathway. The paper supplies biological plausibility and experiments to build on. Individual outcome attribution still requires vascular findings, timing, reperfusion, oxygenation and clinical neurological evidence; the animal result is not a substitute for those observations.
Source: PMC12800310, supplied full-text paper. Findings are paraphrased; forensic implications are an interpretation.
Related: Perampanel Followed Midazolam in a Soman-Exposed Rat Study.